These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37269672)

  • 1. Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo.
    Xiang C; Chen X; Yao J; Yang N; Yu J; Qiu Q; Zhang S; Kong X; Zhao L; Fan ZC; Yu P; Teng YO
    Eur J Med Chem; 2023 Sep; 257():115510. PubMed ID: 37269672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
    Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
    Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
    Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
    Feng Z; Xiang J; Liu H; Li J; Xu X; Sun G; Zheng R; Zhang S; Liu J; Yang S; Xu Q; Wen X; Yuan H; Sun H; Dai L
    J Med Chem; 2022 Feb; 65(3):2571-2592. PubMed ID: 35060744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RLA8-A New and Highly Effective Quadruple PPAR-
    Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
    J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
    Liu L; Liu C; Zhao M; Zhang Q; Lu Y; Liu P; Yang H; Yang J; Chen X; Yao Y
    PLoS One; 2020; 15(12):e0243911. PubMed ID: 33326461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
    Aljobaily N; Krutsinger K; Viereckl MJ; Joly R; Menlove B; Cone B; Suppes A; Han Y
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis.
    Son YJ; Jung DS; Shin JM; Kim M; Yoo G; Nho CW
    BMC Complement Med Ther; 2021 Jan; 21(1):44. PubMed ID: 33494735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trans-anethole attenuates diet-induced nonalcoholic steatohepatitis through suppressing TGF-β-mediated fibrosis.
    Zhang C; Zhang B; Chen A; Yin Q; Wang H
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101833. PubMed ID: 34785385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease.
    Kamata S; Honda A; Ishii I
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alanyl-Glutamine Protects Mice against Methionine- and Choline-Deficient-Diet-Induced Steatohepatitis and Fibrosis by Modulating Oxidative Stress and Inflammation.
    Hu J; Zheng Y; Ying H; Ma H; Li L; Zhao Y
    Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.
    Tanaka N; Takahashi S; Zhang Y; Krausz KW; Smith PB; Patterson AD; Gonzalez FJ
    Biochim Biophys Acta; 2015 Jul; 1852(7):1242-52. PubMed ID: 25736301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
    Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
    Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of methyl palmitate prevents non-alcoholic steatohepatitis (NASH) by induction of PPAR-α.
    Zhang L; Li HX; Pan WS; Ullah Khan F; Qian C; Qi-Li FR; Xu X
    Biomed Pharmacother; 2019 Mar; 111():99-108. PubMed ID: 30579258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
    Zhou Z; Ren Q; Jiao S; Cai Z; Geng X; Deng L; Wang B; Hu L; Zhang L; Yang Y; Li Z
    Eur J Med Chem; 2022 Feb; 229():114061. PubMed ID: 34954593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
    Machado MV; Kruger L; Jewell ML; Michelotti GA; Pereira Tde A; Xie G; Moylan CA; Diehl AM
    Dig Dis Sci; 2016 Jan; 61(1):137-48. PubMed ID: 26403427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chicoric acid attenuate a nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, oxidation, and inflammation in mice with methionine and choline deficiency.
    Kim M; Yoo G; Randy A; Kim HS; Nho CW
    Mol Nutr Food Res; 2017 May; 61(5):. PubMed ID: 27981809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.